http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Rebecca Gall ) (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Dupilumab Efficacy in Patients with GINA-Defined Type 2 Asthma: TRAVERSE
( William W. Busse ),( Eric D. Bateman ),( Ian D. Pavord ),( Nadia Daizadeh ),( Yamo Deniz ),( Paul J. Rowe ),( Juby A. Jacob-nara ),( Rebecca Gall ),( Nami Pandit-abid ),( Benjamin Ortiz ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Background The Global Initiative for Asthma (GINA) 2020 report recommends add-on biologics for patients with type 2 asthma (≥150 blood eosinophils/μL or FeNO ≥20ppb, largely allergen-driven disease). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4/13, key and central drivers of type 2 inflammation. In QUEST (NCT02414854), add-on dupilumab 200/300mg every 2 weeks vs placebo reduced exacerbations and improved forced expiratory volume in 1 second (FEV1) in patients with uncontrolled, moderate-to-severe asthma. TRAVERSE, a single-arm, open-label extension study (NCT02134028), evaluated the long-term safety and efficacy of dupilumab in patients from QUEST. The objective was to assess the long-term efficacy of dupilumab in patients according to baseline type 2 biomarkers and allergic status as suggested by GINA. Methods Patients who received dupilumab or placebo in QUEST received dupilumab 300mg in TRAVERSE for up to 96 weeks. We evaluated annualized severe exacerbation rate (AER) and pre-BD FEV1 in type 2 patients with/without evidence of allergic asthma phenotype (serum total IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L at parent study baseline). Results Dupilumab reduced AERs and improved pre-BD FEV1 in patients with elevated eosinophils or FeNO. These effects were sustained throughout TRAVERSE (Table). Allergic phenotype did not influence the efficacy of dupilumab. Conclusions Dupilumab reduced severe exacerbations and improved FEV1 for up to 96 weeks in patients with type 2 inflammatory asthma as specified in recent GINA recommendations, irrespective of allergic phenotype.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
